Kardigan targets IPO to support cardiology pipeline progression - Pharmaceutical Technology

Kardigan plans to use the IPO funds to push its three in-licensed, mid-to-late-stage heart health therapies down the clinical pipeline. Kardigan plans to use the IPO funds to push its three in-licensed, mid-to-late-stage heart health therapies further down the clinical pipeline. Kardigan plans to use the funds raised in this IPO to progress its pipeline of mid-to-late-stage cardiology candidates. Credit: Alex Syu / Shutterstock.com. Just under a year and a half after its debut, Kardigan is eyeing a listing on the Nasdaq to support the continued development of its in-licensed cardiology pipeline – adding another name to the burgeoning list…

Source: Pharmaceutical Technology